Table 3. Clinical characteristics of the "liquid biopsy" patient cohort subjected to NGS of circulating tumor DNA.*.
| pat. # | category | age [years] | sex | tumor site | stage (AJCC) | KRAS status (initial) | no. of previous therapies | treatments | duration of antibody treatment [months] | response to antibody treatment | disease control at time point of plasma collection |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | panitumum abgroup | 71 | m | rectum | IV | wt | 5 | Folfoxiri/Bev. Folfiri/Pan. SM Reg. Pan-mono | 6 | SD/PD | PD |
| 23 | 49 | m | colon | III | wt | 5 | Ox. Folfiri/Bev. 5-FU/Ox/Pan, Pan. Lri/Mto, Folfox/Bev | 7 | PR/PD | n.e. | |
| 24 | 59 | m | colon | IV | wt | 4 | Folfox/Bev. Pan. Cap/Bev. Fufiri/Bev | 1 | - | - | |
| 25 | 69 | m | CCC | III/IV | wt | 1 | Cis./Gem/Pan, Gem-mono | 6 | SD | SD | |
| 26 | 46 | f | colon/rectum | IV | wt | 4 | Cap/Ox, Muc-1, Folfiri/Pan, Pan-mono, Folfox | 6 | PR/PD | PD | |
| 27 | 63 | m | CCC | IV | wt | 3 | Cis./Gem/Pan, Cis/Gem, Gem/Ox, Cap/Ox | 8 | SD | SD | |
| 28 | cetuximab group | 41 | f | colon/rectum | IV | wt | 1 | Folfiri/Cet | 1 | - | - |
| 29 | 35 | f | CUP | IV | wt | 1 | Carbo/Pacl/Cet | 1 | - | - | |
| 30 | 59 | m | rectum | IV | wt | 3 | Folfox, Cap/Ox, Iri/Cet, Folfiri/Cet, Cap/Ox, Cap-mono | 12 | SD/PD | PR | |
| 31 | 51 | m | rectum | IV | wt | 3 | Folfox/Bev. Folfiri/Ram, Folfox/Cet | 6 | CR | CR | |
| 32 | 44 | m | colon/rectum | I | wt | 2 | Folfox, Folfiri/Cet, Folfox | 6 | PR | PD | |
| 33 | 70 | m | colon | IV | wt | 2 | Folfox/Cet, Folfox/Cet, Folfox, Folfiri, Folfiri/Cet | 17 | PR/PR/PR | SD | |
| 34 | 77 | m | colon | IV | wt | 1 | Folfiri/Cet, Cap | 6 | PR | SD | |
| 35 | 72 | m | colon | III | wt | 2 | Folfox, Iri/Cet | 3 | Pr | PD | |
| 36 | 52 | f | rectum | IV | wt | 3 | Folfiri/Bev, Folfox, Iri/Cet | 9 | n.e. | n.e. | |
| 37 | 74 | f | colon | III | wt | 2 | 5-FU, Folfiri, Folfiri/Cet | 5 | PR | PR | |
| 38 | 71 | f | rectum/sigma | IV | wt | 5 | Folfox, MGN17003, FolfiriBev, Cap/Bev, FolfiriBev, Folfox/Cet. | 6 | PD | PR | |
| 39 | 87 | m | colon | IV | wt | 2 | 5-FUFA, Iri/Cet, Cet | 10 | SD | SD/PD | |
| 40 | 72 | m | sigma | III | wt | 2 | 5-FUFA, Folfox/Cet, Folfiri/Bev | 3 | PR | PR | |
| 41 | 42 | m | sigma | II | wt | 1 | Folfox, Folfox/Cet | 4 | CR | CR | |
| 42 | 54 | f | rectum | III | wt | 1 | 5-FU, Folfiri/Cet, Cap | 6 | PR | PR | |
| 43 | 50 | f | colon | II | wt | 1 | Folfoxiri, Folfiri/Cet | 1 | - | - | |
| 44 | control group (w/o EGFR targeted therapy) | 70 | m | colon | IV | wt | 1 | Cap/Ox | - | - | PD |
| 45 | 53 | m | colon | IV | exon 2 (n.s.) | 1 | Cap/Bev | - | - | SD | |
| 46 | 47 | f | colon | n.e. | cod. 12 (G -> D) | 1 | Folfox/Bev, 5-FUFA/Bev | - | - | SD | |
| 47 | 70 | f | colon | n.e. | cod. 12 (G -> V) | 2 | Cap. Cap/Bev. Folfiri/A fli | - | - | SD | |
| 48 | 74 | f | colon/rectum | IV | cod. 12 (G -> V) | 2 | Folfox/Bev, Cap/Bev, Folfiri, tril-mono | - | - | PD | |
| 49 | healthy control | 29 | f | - | - | - | - | - | - | - | - |
*
Stage refers to the stage at diagnosis; KRAS status was established by routine clinical testing at diagnosis covering exon 2 and 3 mutations; response was valuated according to recist criteria. f = female, m = male, CCC = cholangiocellular cancer, CUP = cancer of unknown primary, wt = wildtype, mut. = mutated, Pan = Panitumumab, Cet = Cetuximab, Bev= Bevacizumab, Ram = Ramucirumab, Reg = Regorafenib, FA = Folic acid, Iri = Irinotecan, Cap = Capecitabne, Gem = Gemcitabine, Mito = Mitomycin-C, Afli = Aflibercept, Cis = Cisplatin, Ox = Oxalilplatin, SM = study medication, CR = complete remission, PR = partial remission, SD = stable disease, PO = progressive disease, n.e. = not evaluated